Different treatment choice for first-line treatment of Helicobacter pylori in an area with a high antibiotic resistance.

We included 90 Hp-infected patients diagnosed histologically. The patients with chronic disease who previously received Hp eradication therapy and underwent gastric surgery were excluded. Patients were randomly divided into 2 groups. The therapy protocol, containing rabeprazole 2x20 mg (Bilim, Kocaeli, Turkey), amoxicillin 2x1 g (Glaxo Smith Kline, İstanbul, Turkey), metronidazole 3x500 mg (I.E. Ulagay, İstanbul, Turkey), and bismuth 2x300 mg (Astellas Pharma Europe B.V., İstanbul, Turkey), was given to the first study group for a period of 1 week and the second study group for a period of 2 weeks. At least 1.5 months after the end of therapy, participants provided a urea breath test (UBT). (Heliprobe analyzer, Wedholm Medical, Kibion, Sweden).